# A Study of DC-CIK to Treat Hepatocellular Carcinoma

> **NCT01821482** · PHASE2 · UNKNOWN · sponsor: **Guangxi Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **BIOLOGICAL:** Dendritic and Cytokine-induced Killer Cells

## Key facts

- **NCT ID:** NCT01821482
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2013-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01821482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01821482, "A Study of DC-CIK to Treat Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01821482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*